Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABSI NYSE:MRK NASDAQ:RXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABSIAbsci$5.74+11.1%$4.04$2.24▼$6.72$888.04M2.364.02 million shs2.27 million shsMRKMerck & Co., Inc.$120.35+0.1%$116.23$75.40▼$125.14$296.99B0.1810.77 million shs2.04 million shsRXRXRecursion Pharmaceuticals$3.25+2.4%$3.26$2.77▼$7.18$1.72B1.0516.62 million shs8.24 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABSIAbsci-2.27%+4.24%+6.39%+83.63%+89.71%MRKMerck & Co., Inc.+0.43%+6.42%+9.06%+0.81%+55.18%RXRXRecursion Pharmaceuticals+7.09%+7.09%-8.91%-15.92%-27.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABSIAbsci$5.74+11.1%$4.04$2.24▼$6.72$888.04M2.364.02 million shs2.27 million shsMRKMerck & Co., Inc.$120.35+0.1%$116.23$75.40▼$125.14$296.99B0.1810.77 million shs2.04 million shsRXRXRecursion Pharmaceuticals$3.25+2.4%$3.26$2.77▼$7.18$1.72B1.0516.62 million shs8.24 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABSIAbsci-2.27%+4.24%+6.39%+83.63%+89.71%MRKMerck & Co., Inc.+0.43%+6.42%+9.06%+0.81%+55.18%RXRXRecursion Pharmaceuticals+7.09%+7.09%-8.91%-15.92%-27.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABSIAbsci 2.57Moderate Buy$7.8236.36% UpsideMRKMerck & Co., Inc. 2.68Moderate Buy$128.186.50% UpsideRXRXRecursion Pharmaceuticals 2.20Hold$8.10149.61% UpsideCurrent Analyst Ratings BreakdownLatest ABSI, MRK, and RXRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2026ABSIAbsci BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$9.005/15/2026MRKMerck & Co., Inc. Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/14/2026RXRXRecursion Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$5.00 ➝ $5.505/14/2026ABSIAbsci Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.105/8/2026ABSIAbsci Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $11.005/7/2026RXRXRecursion Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.005/6/2026MRKMerck & Co., Inc. CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$125.005/1/2026MRKMerck & Co., Inc. Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)5/1/2026MRKMerck & Co., Inc. Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$150.00 ➝ $145.004/30/2026RXRXRecursion Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$11.00 ➝ $10.004/21/2026RXRXRecursion Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABSIAbsci$1.84M486.99N/AN/A$1.10 per share5.21MRKMerck & Co., Inc.$65.01B4.57$11.48 per share10.48$18.60 per share6.47RXRXRecursion Pharmaceuticals$74.68M23.03N/AN/A$1.93 per share1.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABSIAbsci-$115.18M-$0.83N/AN/AN/A-6,450.76%-66.32%-57.01%8/11/2026 (Estimated)MRKMerck & Co., Inc.$18.25B$3.5533.8712.312.6913.59%27.55%10.73%8/4/2026 (Estimated)RXRXRecursion Pharmaceuticals-$644.76M-$1.20N/AN/AN/A-842.95%-54.33%-40.60%8/4/2026 (Estimated)Latest ABSI, MRK, and RXRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026ABSIAbsci-$0.20-$0.19+$0.01-$0.19$1.39 million$0.22 million5/6/2026Q1 2026RXRXRecursion Pharmaceuticals-$0.30-$0.22+$0.08-$0.22$15.78 million$6.47 million4/30/2026Q1 2026MRKMerck & Co., Inc.-$1.47-$1.28+$0.19-$1.72$15.85 billion$16.29 billion3/24/2026Q4 2025ABSIAbsci-$0.16-$0.23-$0.07-$0.20$1.38 million$0.65 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABSIAbsciN/AN/AN/AN/AN/AMRKMerck & Co., Inc.$3.402.82%+5.75%95.77%14 YearsRXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ALatest ABSI, MRK, and RXRX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/26/2026MRKMerck & Co., Inc.quarterly$0.852.84%6/15/20266/15/20267/8/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABSIAbsciN/A6.596.59MRKMerck & Co., Inc.1.021.301.06RXRXRecursion Pharmaceuticals0.015.475.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABSIAbsci52.05%MRKMerck & Co., Inc.76.07%RXRXRecursion Pharmaceuticals89.06%Insider OwnershipCompanyInsider OwnershipABSIAbsci10.49%MRKMerck & Co., Inc.0.17%RXRXRecursion Pharmaceuticals8.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABSIAbsci210155.91 million139.55 millionOptionableMRKMerck & Co., Inc.75,0002.47 billion2.47 billionOptionableRXRXRecursion Pharmaceuticals400529.91 million485.23 millionOptionableABSI, MRK, and RXRX HeadlinesRecent News About These CompaniesVerge, following trial failure, rebrands its AI drug discovery ambitionsMay 27 at 5:44 PM | biopharmadive.comBRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 8.9% Higher - Here's WhyMay 27 at 2:08 PM | marketbeat.comRecursion Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:RXRX)May 27 at 11:54 AM | marketbeat.comRecursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now?May 25 at 11:06 PM | fool.comRecursion Pharmaceuticals (RXRX) Hits 52-Week Low; Is It In Oversold Territory?May 24, 2026 | insidermonkey.comRecursion Pharmaceuticals (RXRX) Hits 52-Week Low; Is It In Oversold Territory?May 24, 2026 | finance.yahoo.comA Look At Recursion Pharmaceuticals (RXRX) Valuation As Mixed Signals Emerge On Future Growth ProspectsMay 23, 2026 | finance.yahoo.comMorgan Stanley Raises its Price Target on Recursion (RXRX)May 22, 2026 | finance.yahoo.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $8.10 Average PT from AnalystsMay 21, 2026 | americanbankingnews.comRecursion Pharmaceuticals (NASDAQ:RXRX) Sets New 52-Week Low - Here's What HappenedMay 19, 2026 | marketbeat.comAltitude Lab Portfolio Companies Surpass $205 Million in Funding, Marking a New Era for Early-Stage Biotechs in Salt Lake CityMay 19, 2026 | finance.yahoo.comAltitude Lab Portfolio Companies Surpass $205 Million in Funding, Marking a New Era for Early-Stage Biotechs in Salt Lake CityMay 19, 2026 | globenewswire.comQ4 Earnings Estimate for RXRX Issued By KeyCorpMay 18, 2026 | marketbeat.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Recommendation of "Hold" by BrokeragesMay 16, 2026 | marketbeat.comRecursion Pharmaceuticals (RXRX): 10 Unrivaled Penny Stocks to Buy NowMay 14, 2026 | finance.yahoo.comRecursion Pharmaceuticals (RXRX): 10 Unrivaled Penny Stocks to Buy NowMay 14, 2026 | insidermonkey.comRecursion Pharmaceuticals (RXRX) price target decreased by 10.64% to 6.12May 14, 2026 | msn.comRecursion Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 13, 2026 | seekingalpha.comRecursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comVanguard Group Inc. Grows Position in Recursion Pharmaceuticals, Inc. $RXRXMay 11, 2026 | marketbeat.comA Look At Recursion Pharmaceuticals (RXRX) Valuation After Clinical Updates And FDA DiscussionsMay 9, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABSI, MRK, and RXRX Company DescriptionsAbsci NASDAQ:ABSI$5.74 +0.58 (+11.14%) As of 12:13 PM Eastern This is a fair market value price provided by Massive. Learn more.Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.Merck & Co., Inc. NYSE:MRK$120.35 +0.11 (+0.09%) As of 12:13 PM Eastern This is a fair market value price provided by Massive. Learn more.Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.Recursion Pharmaceuticals NASDAQ:RXRX$3.24 +0.08 (+2.37%) As of 12:13 PM Eastern This is a fair market value price provided by Massive. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If the Market Rally Stalls, This ETF Can Insulate Portfolios Semtech’s Explosive Rally May Only Be Getting Started The Food Delivery War Just Entered Its Final Phase Bath & Body Works Stock Surged Despite Falling Sales—Here’s Why Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak Dick’s Sporting Goods Isn’t Done Winning Yet Amazon's Alexa for Shopping Strengthens an Already Strong Bull Case TeraWulf Bets on Power Infrastructure to Lead AI Build-Out Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
